European Expert Group of Orphan Drug Incentives
The multidisciplinary and cross-functional expert group brings together representatives of the broad rare disease community, including researchers, academia, patient representatives, members of the investor community, rare disease companies and trade associations.
This group aimed to become the source of ground-breaking ideas and potential solutions that will provide input to the Orphan Medicinal Products (OMP) Regulation Evaluation. The experts have worked together from 2020-2021 and developed fourteen policy proposals throughout the entire orphan drug development path to evolve the OMP landscape. The policy report was presented to the public on 11 June during a dedicated launch event. If you missed the event, you can still watch it here.